Literature DB >> 12925844

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Matthias Edinger1, Petra Hoffmann, Joerg Ermann, Kathryn Drago, C Garrison Fathman, Samuel Strober, Robert S Negrin.   

Abstract

Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation. Suppression of GVHD with maintenance of GVT activity is a desirable outcome for clinical transplantation. We have previously shown that donor-derived CD4+CD25+ regulatory T cells inhibit lethal GVHD after allogeneic bone marrow transplantation across major histocompatibility complex (MHC) class I and II barriers in mice. Here we demonstrate that in host mice with leukemia and lymphoma, CD4+CD25+ regulatory T cells suppress the early expansion of alloreactive donor T cells, their interleukin-2-receptor (IL-2R) alpha-chain expression and their capacity to induce GVHD without abrogating their GVT effector function, mediated primarily by the perforin lysis pathway. Thus, CD4+CD25+ T cells are potent regulatory cells that can separate GVHD from GVT activity mediated by conventional donor T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925844     DOI: 10.1038/nm915

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  472 in total

Review 1.  TGF-beta, T-cell tolerance and anti-CD3 therapy.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

2.  Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.

Authors:  Olivier Joffre; Nathalie Gorsse; Paola Romagnoli; Denis Hudrisier; Joost P M van Meerwijk
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

Review 3.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

Review 4.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

5.  Identification of a unique double-negative regulatory T-cell population.

Authors:  Byung O Lee; Joyce E Jones; Cory J Peters; David Whitacre; Lars Frelin; Janice Hughes; Won-Keun Kim; David R Milich
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

6.  Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.

Authors:  Norifumi Sawamukai; Atsushi Satake; Amanda M Schmidt; Ian T Lamborn; Priti Ojha; Yoshiya Tanaka; Taku Kambayashi
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

7.  Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.

Authors:  Mauro Di Ianni; Paola Olioso; Raffaella Giancola; Stella Santarone; Annalisa Natale; Gabriele Papalinetti; Ida Villanova; Stefano Baldoni; Ambra Di Tommaso; Tiziana Bonfini; Patrizia Accorsi; Paolo Di Bartolomeo
Journal:  Int J Hematol       Date:  2017-07-18       Impact factor: 2.490

Review 8.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

9.  Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.

Authors:  Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O Lightbourn; Cameron S Bader; Warren Alperstein; Norman H Altman; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-08       Impact factor: 5.742

Review 10.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.